Novo Nordisk A/S
Novo Nordisk A/S (NONOF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nonof · stock forecast · 25 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 25 Wall Street analysts in the past 3 months
Buy
25 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $41.92
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $41.06 | ↓ 2.05% |
1-day model range: $40.9–$41.22. Peak: $41.22 (-2.05%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $38 | -9.6% |
| 2028 | $36 | -15.2% |
| 2029 | $34 | -18.7% |
| 2030 | $33 | -20.8% |
| 2031 | — | -22.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NONOF · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-03-27 | BTIG | Maintains | Buy→Buy |
| 2022-12-11 | TD Cowen | Maintains | Outperform→Outperform |
| 2022-06-27 | UBS | Downgrade ↓ | Neutral→Sell |
| 2022-06-06 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2022-05-30 | Guggenheim | Upgrade ↑ | Neutral→Buy |
| 2022-03-15 | Deutsche Bank | Upgrade ↑ | Hold→Buy |
| 2022-01-24 | Liberum | Downgrade ↓ | Hold→Sell |
| 2021-12-19 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2020-01-02 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2019-11-17 | Barclays | Upgrade ↑ | Equal Weight→Overweight |
Wall Street analysts have recently issued updated ratings on Novo Nordisk A/S (NONOF) stock. Of the recent 52 rating actions, 25 were upgrades and 22 were downgrades. 25 analysts currently cover NONOF.
Analyst Recommendation Trends
NONOF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$292.2B
↓ 8.7% YoY
Revenue Next Year
$299.4B
↑ 2.5% YoY
EPS This Year
$21.68
EPS Next Year
$21.46
↓ 1.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast NONOF EPS of $21.68 for the current fiscal year, based on estimates from 1 analysts. The NONOF revenue forecast is $292.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NONOF stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NONOF price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The NONOF short-term stock prediction for tomorrow is $41.06 (-2.05%). The NONOF stock price prediction for 2027 estimates an average of $38. The NONOF stock prediction for 2030 projects a range of $32–$35.
Novo Nordisk A/S trades on OTC under the ticker NONOF. The NONOF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 72% of covering analysts.
Frequently asked questions
NONOF forecast · 8 questionsAccording to 25 Wall Street analysts, the average 12-month NONOF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $41.92.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.